Clinical trials: Pancreatic Cancer
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or…
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation
- Trial name
- NCT06922591
- Testing
- TNG462, RMC-9805, RMC-6236
- Where
- 18 sites in United States
- Volunteers
- 183 people
- Sponsor
- Tango Therapeutics, Inc.
Carcinoid Syndrome, Carcinoid
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome.
- Conditions
- Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
- Trial name
- NCT05361668
- Testing
- Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 36 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Pancreatic Cancer, Solid Tumor, Adult
U87 CART in Treatment of Advanced Solid Tumor
This is a single center, open-label, phase 1 study to evaluate the safety and efficacy of U87 CART in treating advanced solid tumor .
- Trial name
- NCT05605197
- Testing
- U87 CAR-T
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Pancreatic Cancer
A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer
The purpose of this study is to test the safety and determine the optimal dose of a new experimental drug, demcizumab (OMP-21M18), when given in combination with gemcitabine with or without (+/-) Abraxane®.
- Trial name
- NCT01189929
- Testing
- Demcizumab, Abraxane®, Gemcitabine
- Where
- 6 sites in Australia, New Zealand and 1 more
- Volunteers
- 57 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Pancreas Cancer
Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)
This is an interventional, single-arm, open-label study with high dose short course radiotherapy for patients with locally advanced pancreatic cancer.
- Trial name
- LAPC (NCT05191940)
- Testing
- Particle-therapy using protons or carbon ions, Blood sampling, Magnetic resonance imaging
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- EBG MedAustron GmbH
Gastrointestinal Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05262491
- Testing
- BL-B01D1
- Where
- 6 sites in China
- Volunteers
- 96 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors.
- Trial name
- NCT07488676
- Testing
- ASP546C
- Where
- 21 sites in United States, Japan
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced Solid Tumor
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid…
- Trial name
- NCT06959615
- Testing
- JAB-23E73
- Where
- 32 sites in China
- Volunteers
- 334 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Breast Cancer, Gastric Cancer
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry…
- Conditions
- Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer
- Trial name
- NCT06695845
- Testing
- Zanidatamab
- Where
- 42 sites in United States, Georgia and 2 more
- Volunteers
- 200 people
- Sponsor
- Jazz Pharmaceuticals
Colorectal Cancer, Triple Negative Breast Cancer
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
The purpose of this trial is to evaluate changes in immune activity relative to baseline following treatment with Toca 511 and Toca FC in patients with solid tumors (including recurrent high grade glioma [rHGG]) or lymphoma.
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT02576665
- Testing
- Toca 511, Toca FC
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tocagen Inc.
Pancreatic Cancer
A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastatic Pancreatic Cancer
This is a multicenter, open-label, Phase II umbrella study conducted in participants with advanced or metastatic pancreatic cancer.
- Trial name
- NCT07814066
- Testing
- SKB571
- Volunteers
- 30 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Dose Escalation, Safety
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies.
- Conditions
- Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors
- Trial name
- NCT01576666
- Testing
- LDE225, BKM120
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Adenocarcinoma of the Pancreas
Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase 1b, Open-Label, Safety, Pharmacokinetic, and Pharmacodynamic Study of an Anti-super-enhancer Minnelide Once a Day on Days 1 to 5, Days 8 to 12 and Days 15 to 19 Along with Abraxane Plus Gemcitabine in Patients with…
- Trial name
- NCT05557851
- Testing
- Minnelide
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Minneamrita Therapeutics LLC
Pancreatic Cancer, Colorectal Cancer
Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
A multi-center Phase 1b/2 study testing the combination of AMG 820 and pembrolizumab in subjects with select advanced solid tumors.
- Conditions
- Pancreatic Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT02713529
- Testing
- AMG820 and pembrolizumab
- Where
- 15 sites in United States, Australia and 4 more
- Volunteers
- 117 people
- Sponsor
- AmMax Bio, Inc.
Advanced Solid Tumor, Metastatic Cancer
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the…
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer
- Trial name
- NCT04464967
- Testing
- SNK01, Trastuzumab, Cetuximab
- Sponsor
- NKGen Biotech, Inc.
Pancreatic Neoplasm
Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer
The main objective of the study was to evaluate the effectiveness of aflibercept treatment by comparison to placebo in increasing the overall survival (OS) in participants with metastatic pancreatic cancer, treated with…
- Trial name
- VANILLA (NCT00574275)
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Gemcitabine
- Where
- 24 sites in United States, Argentina and 22 more
- Volunteers
- 546 people
- Sponsor
- Sanofi
Locally Advanced and Metastatic Pancreatic Cancer
NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia
The purpose of this study is to determine the recommended dose of NC-6004 according to the dose-limiting toxicity (DLT) in combination with Gemcitabine, and to assess the efficacy, safety and tolerability.
- Trial name
- NCT00910741
- Testing
- Nanoplatin (NC-6004) and Gemcitabine
- Where
- 5 sites in Singapore, Taiwan
- Volunteers
- 40 people
- Sponsor
- NanoCarrier Co., Ltd.
Pain, Pancreatic Cancer
Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer
CUC10-PAN09 will evaluate the safety and efficacy of cryoablation therapy on the relief of epigastric/abdominal pain associated with pancreatic cancer.
- Trial name
- NCT01335945
- Testing
- Cryoablation
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Boston Scientific Corporation
Locally Advanced Pancreatic Adenocarcinoma
OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy
The OSPRItaly Patient Registry has been developed to assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with…
- Trial name
- OSPRItaly (NCT06399172)
- Testing
- OncoSil
- Volunteers
- 50 people
- Sponsor
- OncoSil Medical Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.